Cipher Pharmaceuticals Inc.
CPHRF
$7.50
-$0.35-4.46%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 26.46M | 22.16M | 22.14M | 21.16M | 21.15M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 26.46M | 22.16M | 22.14M | 21.16M | 21.15M |
| Cost of Revenue | 5.09M | 4.19M | 4.15M | 4.07M | 4.05M |
| Gross Profit | 21.38M | 17.97M | 18.00M | 17.09M | 17.10M |
| SG&A Expenses | 8.68M | 5.77M | 5.71M | 5.43M | 5.16M |
| Depreciation & Amortization | 2.78M | 1.12M | 1.17M | 1.23M | 1.30M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.58M | 11.12M | 11.17M | 10.86M | 10.65M |
| Operating Income | 9.88M | 11.04M | 10.97M | 10.30M | 10.51M |
| Income Before Tax | 9.49M | 12.29M | 12.94M | 12.68M | 11.93M |
| Income Tax Expenses | -6.37M | -10.32M | -9.74M | -7.70M | -20.48M |
| Earnings from Continuing Operations | 15.86 | 22.60 | 22.68 | 20.38 | 32.41 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 15.86M | 22.60M | 22.68M | 20.38M | 32.41M |
| EBIT | 9.88M | 11.04M | 10.97M | 10.30M | 10.51M |
| EBITDA | 12.57M | 12.07M | 12.06M | 11.44M | 11.71M |
| EPS Basic | 0.66 | 0.92 | 0.92 | 0.82 | 1.29 |
| Normalized Basic EPS | 0.29 | 0.32 | 0.33 | 0.32 | 0.30 |
| EPS Diluted | 0.63 | 0.89 | 0.89 | 0.79 | 1.26 |
| Normalized Diluted EPS | 0.29 | 0.32 | 0.33 | 0.32 | 0.30 |
| Average Basic Shares Outstanding | 97.54M | 97.67M | 98.90M | 100.02M | 100.88M |
| Average Diluted Shares Outstanding | 99.44M | 99.44M | 100.60M | 101.75M | 102.51M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
